As TNF-a is a key proapoptotic factor, monoclonal antibodies targeting TNF-a such as Infliximab and Etanercept may theoretically be beneficial; however, studies testing their use in low-risk MDS have found variable to minimal impact [77,78]. This evidence concerns the gene TNF and myelodysplastic syndrome.